Spero Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
SPRO$1.01-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues: | ||
| Grant revenue | $7,046 | $4,930 |
| Collaboration revenue - related party | 95,802 | 46,076 |
| Collaboration revenue | 933 | 2,503 |
| Total revenues | 103,781 | 53,509 |
| Operating expenses: | ||
| Research and development | 51,440 | 47,593 |
| General and administrative | 25,554 | 36,483 |
| Impairment of long-term asset | 5,306 | — |
| Restructuring | — | 11,630 |
| Total operating expenses | 82,300 | 95,706 |
| Income (loss) from operations | 21,481 | (42,197) |
| Other income (expense): | ||
| Interest income | 3,937 | 1,106 |
| Other income (expense), net | (14) | (55) |
| Interest expense related to the sale of future royalties | — | (2,605) |
| Loss on extinguishment of liability related to the sale of future royalties | — | (3,581) |
| Change in fair value of derivative liability | — | 917 |
| Total other income (expense), net | 3,923 | (4,218) |
| Net income (loss) before income taxes | 25,404 | (46,415) |
| Income tax expense | (2,598) | — |
| Net income (loss) | $22,806 | $(46,415) |
| Net income (loss) per share attributable to common stockholders, basic | $0.43 | $(1.23) |
| Net income (loss) per share attributable to common stockholders, diluted | $0.43 | $(1.23) |
| Weighted average common shares outstanding, basic: | 52,703,467 | 37,585,075 |
| Weighted average common shares outstanding, diluted: | 52,989,030 | 37,585,075 |
| Comprehensive income (loss): | ||
| Net income (loss) | 22,806 | (46,415) |
| Other comprehensive gain (loss): | ||
| Unrealized gain on marketable securities | — | 2 |
| Net unrealized gains (losses) on securities | — | 2 |
| Total comprehensive income (loss) | $22,806 | $(46,413) |
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.